Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837365 | 0.90 | KMT2A (0.39) | KMT2AMEN1KAT2BATMGPR139 | |
| SCHEMBL2835049 | 0.88 | KMT2A (0.39) | KMT2AMEN1KAT2BGPR139ALDH1A1 | |
| SCHEMBL2834005 | 0.87 | KMT2A (0.38) | KMT2AMEN1KAT2BGPR139LMNA | |
| SCHEMBL2149496 | 0.87 | GPR139 (0.40) | KMT2AMEN1KAT2BATMGPR139 | |
| SCHEMBL2837239 | 0.87 | KMT2A (0.38) | KMT2AMEN1KAT2BGPR139HTT | |
| SCHEMBL2149306 | 0.86 | CA12 (0.37) | KMT2AMEN1KAT2BATMHTT | |
| SCHEMBL2835040 | 0.86 | GPR139 (0.39) | KMT2AMEN1KAT2BGPR139HTT | |
| SCHEMBL2830804 | 0.86 | KMT2A (0.38) | KMT2AMEN1KAT2BGPR139 | |
| SCHEMBL2149368 | 0.86 | KMT2A (0.43) | KMT2AMEN1KAT2BATMGPR139 | |
| SCHEMBL2831445 | 0.85 | CNR2 (0.41) | KMT2AMEN1ATMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342182-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-11-14 | — | — | EP | claimed |
| US-8242134-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-08-14 | — | — | US | claimed |
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-25 | — | — | US | claimed |
| US-20210371385-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF | SOJOURNIX INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210371385-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF | SOJOURNIX INC (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3784244-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF | Sojournix, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3784244-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF | Sojournix, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112384221-A | Polymorphic and amorphous forms of isoquinolinones and methods of use thereof | 索约尼克斯公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-112384221-A | Polymorphic and amorphous forms of isoquinolinones and methods of use thereof | 索约尼克斯公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20200216396-A1 | DEUTERATED FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF | SOJOURNIX, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200216396-A1 | DEUTERATED FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF | SOJOURNIX, INC. | 2020-07-09 | — | — | US | disclosed |
| US-8242134-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-08-14 | — | — | US | disclosed |
| US-8242134-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-08-14 | — | — | US | disclosed |
| US-8242134-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-08-14 | — | — | US | disclosed |
| EP-2342182-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2011-07-13 | — | — | EP | disclosed |
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-25 | — | — | US | disclosed |
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-25 | — | — | US | disclosed |
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-25 | — | — | US | disclosed |
| WO-2010028655-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010028655-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | KMT2A 891/4885MEN1 2461/4885KAT2B 3039/4885 |
| US-20210371385-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF | HLA-DRB1, HLA-B, APBA1 | KMT2A 568/4885MEN1 4278/4885KAT2B 803/4885 |
| US-20200216396-A1 | DEUTERATED FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF | CYP8B1, SDHA, COQ8B | KMT2A 1086/4885MEN1 2597/4885KAT2B 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.